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Background and purpose: In breast cancer patients receiving radiotherapy, 
accurate target delineation and reduction of radiation doses to the nearby normal 
organs is important. However, manual clinical target volume (CTV) and 
organs-at-risk (OAR) segmentation for treatment planning increases physicians’ 
workload and inter-physician variability considerably. In this study, we first 
evaluated the feasibility of a deep learning-based auto-segmentation (DLBAS) 
in comparison to atlas-based segmentation solutions (ABAS) for breast 
radiation therapy. Secondly, we evaluated the clinical utility of 
proposed-DLBAS from a clinician’s perspective. Lastly, external validation was 
conducted.   
Methods and materials: CTVs and OARs were generated by one expert on 
planning CT scans of breast cancer patients. Auto-contours were generated 
using convolutional neural network algorithm. First, accuracy of DLBAS was 
compared with ABAS using Dice similarity coefficient (DSC) and 95% 
Hausdorff distance (HD). Secondly, additional qualitative scoring of DLBAS 
and dose-volume histograms with dosimetric parameters were analyzed. Lastly, 
11 experts from two institutions were asked to participate in this external 
validation. Each contour of DLBAS and 11 manual contours were compared 




Results: Compared to ABAS, the proposed DLBAS model yielded more 
consistent results and the highest average Dice similarity constant and lowest 
Hausdorff distances, especially CTVs and the substructures of the heart. ABAS 
showed limited performance in soft-tissue-based regions, such as the esophagus, 
cardiac arteries, and smaller CTVs. The results of sensitivity analysis between 
contrast and non-contrast CT test sets showed little difference in the 
performance of DLBAS and conversely, a large discrepancy for ABAS. 
Secondly, qualitative subjective scoring showed that the results were acceptable 
for all CTVs and OARs, with a median score of at least 8 (possible range: 0–10) 
for (1) the differences between manual and auto-segmented contours and (2) the 
extent to which auto-segmentation would assist physicians in clinical practice. 
The differences in dosimetric parameters between the auto-segmented and 
manual contours were minimal. In external validation, Total mean time for 9 
OARs was 37±20 min for manual and 6±5 min for corrected-auto-contours. 
Among the DSC of experts’ manual contours and an auto-contour, DSC of an 
auto-contour ranked the second place and HD ranked the first place. Among 
manual OARs, breast contours had the largest variations, which were most 
significantly improved with an aid of ACS. 
Conclusions: The feasibility of deep learning-based auto-segmentation in breast 
RT planning was demonstrated. Although deep learning-based 
auto-segmentation cannot be a substitute for radiation oncologists, it is a useful 
tool with excellent potential in assisting radiation oncologists in the future. 
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Breast cancer is the most common cancer among women in many countries, 
accounting for 1 in 4 newly diagnosed cancers.1 Moreover, it is the leading 
cause of cancer deaths in women in over 100 countries. As an integral part of 
the curative treatment for patients with breast cancer, the clinical utilization of 
radiation therapy (RT) has increased in recent decades. Thus, in this era of 
three-dimensional conformal and intensity-modulated RT, precise delineation of 
the clinical target volume (CTVs) and the organ at risk (OAR) has become vital. 
The requirements for accurate delineation of delicate target volumes for 
regional node irradiation have increased with the availability of recent data from 
the EORTC 22922-10925,2 MA.20,3 and DBCG-IMN trials.4 We have 
previously reported that an individualised target volume is recommended even 
for patients in the modern management era.5,6 Because the majority of patients 




of experiencing long-term adverse events, including lymphedema,7 radiation 
pneumonitis,8 hypothyroidism,9 and cardiotoxicity,10 which can substantially 
decrease quality of life.  
 
Modern RT planning is a complex process that relies on computed tomography 
(CT)-based three-dimensional imaging as well as an expert team.11 Based on CT 
simulations, radiation oncologists contour the relevant target volumes and 
surrounding normal structures and communicate with the dosimetrist the 
anticipated dosimetric goals that will deliver a therapeutic radiation dose to the 
target while sparing the OARs. In contrast to other primary malignancies such 
as lung and head & neck cancer, modern RT planning has not been not 
commonly applied to breast cancer, in which conventional formulaic field-based 
planning and two-dimensional techniques were predominantly used 12. Currently, 
in RT planning, OARs and CTVs are manually segmented by radiation 
oncologists following international contour guidelines, such as the ESTRO and 
RTOG guidelines.13 However, given the typical number and complexity of the 
structures involved, delineation is a laborious and often time-consuming task. 
Additionally, as the outcome is highly dependent on the skill of the observer, a 
significant amount of inter-observer variation exists. A previous study showed 
that the contours from multiple observers had low structural overlap with 
volume variations of up to 60%, which would likely result in substantial 
variations in RT dosimetric planning.14 Quality issues and inter-physician 
variations of target volumes and OAR contours have been of particular concern 
arising from dummy runs, multi-institutional studies, individual case reviews 
and audit studies.15,16 Uncertainties regarding volume delineation and 
subsequent target and normal tissue doses may not only decrease the treatment 





Recognizing the limitations of the manual segmentation process, recent 
developments in auto-segmentation have gained significant attention for their 
potential application in routine clinical workflows. One solution that is currently 
available is atlas-based auto-segmentation (ABAS); to date, several commercial 
ABAS solutions have been released. There have been numerous studies 
evaluating ABAS for use in cancer sites such as the head and neck,17 prostate,18 
and lungs.19 However, ABAS has several limitations, including insufficient 
contour results for structures with low contrast, slow image registration, and the 
need for additional correction time to improve segmentation accuracy.20  
 
More recently, with the increase in available computational power and the 
reduction of financial barriers, most research focus has shifted towards deep 
learning-based auto-segmentation (DLBAS) approaches.21 With recent advances 
in computing power, algorithms, and data collection, artificial intelligence (AI) 
is increasingly being used in health care to assist physicians. In radiation 
oncology, there are numerous areas in which AI is applicable, such as target and 
normal tissue segmentation, dose optimization, decision support systems, 
application of predictive models, and quality assurance 22-24. Auto-contouring 
tools have been adopted by an increasing number of physicians and have 
resulted in improved efficiency, particularly for OARs in head and neck cancer 
and target volume in prostate cancer 25,26.  
 
The first aim of this study is to evaluate commercially available ABAS and 
DLBAS methods used for delineating RT planning structures (CTVs and OARs) 
for breast cancer. As there is a paucity of data regarding the auto-segmentation 
of target volumes and OARs in breast RT planning, secondly, we attempted to 
train a DLBAS model for target volumes and OARs for breast cancer and 




externally validate the performance of the auto-contouring system, by 
comparing it with the manual contours of experts. We also examined whether 
the use of auto-contouring system in breast cancer radiotherapy would reduce 
the workload of radiation oncologists, promote accuracy of delineating OARs, 





II. MATERIALS AND METHODS 
 
1. COMPARISON with ABAS  
 
Sixty-two breast cancer patients, with a mix of left- and right-sided breast 
cancer, who received RT after breast-conserving surgery between May 1st, 2016 
and May 1st, 2019 and underwent contrast-enhanced planning CT were selected 
for this study after Institutional Review Board approval. The CT scans were 
acquired on a Siemens Sensation Open (Siemens, Forchheim, Germany) and a 
Toshiba Aquilion (Toshiba Medical Systems, Japan), using the following 
common CT image acquisition protocols: 120 kVP, 3 mm CT slice thickness, 
and the patient in supine position with both arms up.  
 
The expert contours were manually delineated by a single experienced radiation 
oncologist with over 10 years of experience who is currently treating over 500 
breast cancer patients per year, all of whom are undergoing adjuvant RT with 
volumetric modulated arc therapy. For these patients, the planning contours 
included a full list of OARs and CTVs drawn following the ESTRO guidelines, 
to evaluate the performance of each software package in a realistic clinical 
workflow, which often involves the delineation of all of these structures. We 
included various types of CTVs, such as the axillary (AXL) Level 1-3, internal 
mammary (IMN), and supraclavicular lymph nodes (SCL). In the case of the 
supraclavicular nodes, we included both versions suggested by ESTRO (E) and 
RTOG (R) guidelines. In addition to other OARs (right and left lung, esophagus, 
spinal cord, and thyroid), we also evaluated the segmentation of heart 
substructures for further consideration of cardiotoxicity: right and left atrium, 






In addition, to test each algorithm’s robustness to input data type, we conducted 
a sensitivity analysis by comparing the extent of change in Dice Similarity 
Coefficient (DSC) and 95% Hausdorff Distance (HD) of three segmentation 
models using 14 non-contrast CT scans. These scans were acquired using 
similar acquisition protocols as the contrast-enhanced CT sets and included all 
contour structures except for heart substructures. 
 
Two commercial systems that perform user-defined ABAS— Mirada’s 
Workflow Box (WFB, Mirada Medical, Ltd., Oxford, UK) and MIM Maestro 
(MIM Software Inc., Cleveland, OH)—were used to automatically segment 
target structures. We constructed an atlas library database for each software 
package that consists of the data from 35 patients and the corresponding expert 
contours.  
 
In MIM, the first step in building an atlas was to assign a randomly selected 
reference or “template” subject. The remaining subjects were registered to the 
template one by one, along with the expert contours. Although MIM offers a 
tool to edit the registration alignment, to obtain a non-biased auto-segmentation 
and keep the experimental settings as consistent as possible, we did not 
intervene during registration and segmentation. The final step was the 
segmentation process itself. In MIM, under the “Atlas Segment” tool, we 
selected the contours and ran the segmentation with the following default 
settings: Number of Match = 1, Mirroring Enabled and Multicontour 
finalisation method = Majority Vote. Next, because a single atlas segmentation 
was selected, the algorithm automatically searched for the atlas subject that best 
matched the input CT. Then, expert contours of the atlas subject were deformed, 




cubic spline interpolation.  
 
In Mirada, a workflow that linked the atlas created by the user and the 
segmentation operation was created that simply required selecting the input CT 
and assigning it to the workflow in a single click. As it functions like a black 
box, it is not possible to change settings in WFB. Also, unlike MIM, WFB does 
not require the assignment of template patients or any further user intervention. 
The construction of the library simply involved selecting CT scans and their 
corresponding structures. Once every subject was added, the atlas files were 
uploaded to the WFB server. 
 
In this study, we developed a two-step of three-dimensional (3D) fully 
convolutional DenseNet (FCDN) to automatically contour the target structures 
in a semantic manner, as originally proposed by Jegou et al..27 More detailed 
information regarding the two-step approach is included in the Supplementary 
data. The FCDN network was trained on an NVIDIA TITAN RTX GPU with 
Tensorflow in Python, using the same 35 patient scans as in Section 2.2, over 
200 training epochs, with 13 patient scans used for validation. 
 
As shown in Figure 1, the FCDN architecture is made up of dense blocks that 
resemble the residual blocks in a U-Net architecture. Following the convolution 
layer, the transition down layers consist of BN, RELU, 1 × 1 convolution, 
dropout (p = 0.2), and a 2 × 2 max pooling operation. The skip connection 
components represent the concatenation of the feature maps from the 
down-sampling path with those in the up-sampling path, thereby ensuring a 
high-resolution output. Finally, the transition up (TU) layers consist of 3 × 3 






Fig. 1. The schematic of the proposed FCDN. 
 
The accuracy of each segmentation method was assessed with 14 test patients 
using the DSC and HD. The manual contours delineated by a single expert (RO) 
were considered ground truth in this study, against which the ABAS and FCDN 
contours were compared. DSC is a metric that quantifies the closeness of the 
automated and expert contours, defined as double the overlap of the two 
contours divided by the sum of their individual volumes.  
 
The range of the Dice scores is [0, 1] where 1 indicates a perfect match between 
the two contours and 0 indicates no overlap at all. In this study, a Dice score of 
0.75 was considered an acceptable match. HD describes the largest 
surface-to-surface separation among the 95th percentile of surface points of 
ground truth and segmentation. Similar procedures were repeated for the 
robustness analysis using 14 non-contrast CT test samples. 
 
A pairwise t-test was conducted to determine if there was a statistically 




Since there are three segmentation methods to compare, we adopted Bonferroni 
correction to address the multiple-comparison correction with n = 3 and the 
alpha value adjusted to 0.0167 (0.05/3). A p-value of less than 0.0167 was 
determined to be a rejection of the null hypothesis and therefore a statistically 
significant result. 
 
2. INVESTIGATION OF CLINICAL USEFULNESS  
 
It included 111 breast cancer patients who received adjuvant RT after 
breast-conserving surgery. Both left-sided and right-sided breast cancer patients 
were included. The median age of the patients was 51 years (range, 28–77 
years) and the median body mass index was 22.5 kg/m2 (range, 17.03–35.4 
kg/m2). For T stage, 15 patients were Tis (14%), 60 patients were T1 (54%), 33 
patients were T2 (30%), and 3 patients were T3 (3%). For N stage, 82 patients 
were N0 (74%), 26 patients were N1 (23%), and 3 patients were N2 (3%). RT 
field included whole breast only for 79 patients (71%) and WB with regional 
lymph nodes for 32 patients (29%). Both non-contrast (n = 50) and 
contrast-enhanced (n = 61) planning CT scans were used for manual delineation 
of CTVs and OARs. Planning CT scan (Somatom Sensation Open syngo CT 
2009E, Siemens and Aquilion TSX-201A, Toshiba) was performed 
approximately two weeks prior to RT with a CT slice thickness of 3 mm. The 
setup position for all planning CT scans was the supine position with both arms 
held up using an arm support device (CIVICO). Contrast-enhanced planning CT 
was performed 1 min after administration of 80–90 mL intravenous contrast 
(iohexol, 84.11 g / 130 mL; depending on the patient’s weight).  
 
Previous contours used for patient treatment were not used in this study. For 




approximately 550 breast cancer patients per year contoured the CTVs and 
OARs within 1 month, with the patients’ clinical information blinded. The target 
volume consisted of CTVs of right and left breasts (CTVp_breast); axillary 
levels 1, 2, and 3 (CTVn_L1, L2, L3); internal mammary chain (CTVn_IMN); 
and lymph node level 4 (CTVn_L4), which is supraclavicular lymph node 
delineated according to the ESTRO guidelines 28. In our study, we included 
interpectoral nodes mentioned in the ESTRO guidelines in CTVn_L2. In 
addition, the supraclavicular lymph nodes were additionally delineated 
according to the RTOG guidelines (CTVn_SCL RTOG).29 The OARs included 
the heart, right and left lungs, esophagus, spinal cord, and thyroid.30  
 
To segment the CTVs and OARs, a convolutional neural network (CNN) was 
used, which combined a U-Net with EfficientNet-B0 as the backbone (Figure 
2).31 In EfficientNet, 3D convolutional layers are used to exploit the 3D 
structural information.32 For inputs of the CNN, all cases were resampled to a 
voxel spacing of 1.0×1.0×3.0 mm3 and then the image intensity values of a 
truncated range of [-160, 240] were normalized into the range of [0, 1]. Owing 
to GPU memory limitations, the CNN was trained in the patch level, with a size 
of 128×128×64. Furthermore, we trained the CNN with the sum of 
cross-entropy and dice loss, and we used RMSprop optimizer with an initial 
learning rate of 5×10-4 and weight decay of 10-4.33 During training, we applied 







Fig 2. Schematic of the proposed convolutional neural network architecture 
(U-Net with EfficientNet-B0) 
 
Among 111 cases that were newly contoured by an expert, a total of 92 cases 
were used as training dataset and 19 cases were used as test dataset #1 (contrast: 
10 cases, non-contrast: 9 cases) for the analysis of quantitative metrics. Test 
dataset #2 was prepared separately to analyze the efficacy of auto-segmented 
contours using real-world heterogeneous data. Dosimetric parameters were 
analyzed using different sets of CT scans with manual contours (previously used 
for patient treatment) delineated by various physicians and RT plans of breast 
cancer patients who received RT after surgery (n = 42). 
 
Both quantitative metrics and qualitative scoring were used for analyzing test 
dataset #1. Quantitative metrics included the most used geometrical indices, 
such as DSC and HD, to compare the auto-segmented and manually delineated 
contours. DSC is a measure of overlap between two contours, from “0” to “1,” 
where “1” indicates a complete overlap. HD is the measure of distance between 




two panels—an expert breast cancer radiation oncologist panel (n = 11) and a 
non-expert panel that included residents and radiation oncologists whose 
specialty is not breast cancer (n = 15)—from 10 institutions answered the 
following questions after watching an example video on manual contouring and 
auto-segmentation contouring on a planning CT scan: 
 
What score would you give for the differences between manually delineated 
contours and auto-segmentation contours? (Difference scores) 
 
 Answer: 0 (most different) to 10 (least different) 
 
How much do you think auto-segmentation would assist you in real-world 
clinical practice? (Assistance scores) 
 
 Answer: 0 (not helpful) to 10 (very helpful) 
 
To analyze test dataset #2, auto-segmented contours were generated in 42 
patients’ CT scans, and dose-volume histograms were analyzed using both 
auto-segmented contours and original manual contours. Furthermore, dosimetric 
analysis was performed by comparing the mean dose (Gy), D0.03cc (Gy), and 
V5Gy (cc) for heart; mean dose (Gy), V20Gy, (%), and V5Gy (%) for ipsilateral 
lung; mean dose for contralateral lung; D0.03cc (Gy) for esophagus; and D1cc 
(Gy) for spinal cord for the manual and auto-segmented contours.  
 
Additionally, inter-user variability was assessed by analyzing the DSCs and 
HDs of contours delineated by three different radiation oncologists on a 
randomly selected CT scan of a breast cancer patient. Furthermore, contouring 




for manual delineation with that for auto-segmentation. Although the 
differences between the auto-segmented contours and manual contours were 
assessed quantitatively, in the field of radiation oncology, there is no precise 
answer or gold standard for CTV and OAR contours. Thus, differences do exist 
between contours delineated by different radiation oncologists. Table 1 shows 
the inter-observer variability through DSC and 95% HD for OARs and CTVs 
delineated by three board-certified radiation oncologists for a randomly selected 
patient. For OAR, only the heart and lungs showed a DSC above 0.80, whereas 
the other organs showed DSCs lower than 0.80. For CTV, although breast CTV 
showed an acceptable mean DSC of 0.85, other CTVs such as CTVn_L1, L2, 
L3, CTVn_IMN, CTVn_L4, and CTVn_SCL showed poor results, with mean 
DSC ranging from 0.45 to 0.75. For this randomly selected case, the contouring 
times for the three radiation oncologists were 35, 40, and 42 min, respectively, 
whereas the time taken to obtain auto-segmented contours was less than 10 min, 






Table 1. Inter-observer variability of manual contours of organs-at-risk and 
target volumes 
  DSC STD   95% HD (mm) STD (mm) 
Organs-at-risk           
Heart 0.91 0.01  13.00 5.10 
Rt Lung 0.99 0.00  2.33 0.95 
Lt Lung 0.98 0.00  2.19 0.66 
Thyroid 0.72 0.07  5.37 1.70 
Esophagus 0.78 0.04  7.08 3.52 
Spinal cord 0.69 0.09  72.89 49.91 
Target      
CTVp_breast 0.85 0.02  8.94 2.86 
CTVn_L1 0.69 0.04  13.58 3.00 
CTVn_L2 0.47 0.17  18.74 8.15 
CTVn_L3 0.56 0.10  9.87 3.61 
CTVn_IMN 0.53 0.09  35.11 17.46 
CTVn_L4 0.45 0.13  11.82 4.88 
CTVn_SCL RTOG 0.75 0.03   6.93 0.62 
 
 
3. EXTERNAL VALIDATION  
 
Eleven experts who have a median of 7 (range, 2–21) years’ experience of 
breast cancer radiotherapy was volunteered to participated in this study. The 
experts are attendings (n=2), clinical fellows (n=6), residents (n=2), and a 
dosimetrist (n=1) from two institutions (Yonsei Cancer Center and Asan 
Medical Center). Firstly, the 11 experts were requested to manually delineate 
OARs of breast cancer radiotherapy on simulation CT scans of 10 women 
planning to undergo radiotherapy for breast cancer (manual contours). The 9 




right breast, and left breast. Secondly, auto-contouring system was conducted 
for the same simulation CT scans and these auto-contours were provided to the 
experts. The experts were asked to correct the auto-contours as needed 
(corrected-auto-contours). Before contouring, the CT scans were de-identified, 
and the clinical information of patients was blinded. The clinical treatment 
contours that were used for the patient’s radiotherapy delivery were removed to 
avoid bias during contouring. The experts were asked to record the video during 
the contouring for each CT scan using screen-recording software (oCam, 
OHSOFT, Korea). Additionally, as an exploratory analysis, a medical student 
with no experience in breast cancer radiotherapy performed the same procedure. 
This student's contouring metric data were shown in Fig 11 and not included in 
any other analyses. 
 
Then, the best manual contours for each simulation CT were selected as ground 
truth after blind review by an independent third-party committee which 
consisted of five attending radiation oncologists who regularly treat breast 
cancer and have experience in breast cancer radiotherapy for more than 10 years. 
This review of contours was conducted online using a Google questionnaire 
platform without information on who contoured. Using these ground truths, 
accuracy was compared between the manual, corrected-auto, and auto-contour 
groups.  
 
Each manual, corrected-auto-, and auto-contour was compared to the best 
manual contour using DSC and HD. Next, the sensitivity analysis was 
conducted; each contour was compared to the second-best manual contour, 
instead of the first-best manual contour, using DSC and HD. Whether the results 
achieved with the second-best manual contour are consistent with the primary 




the time-saving effect, recorded videos on contouring were centrally reviewed 
and contouring times for all 9 OARs and for each OAR were measured. The 
time for manual contouring and correcting the auto-contours were compared. 
(3) To evaluate user satisfaction, simple questionnaires were sent to 11 experts 
to estimate the efficacy and feasibility of using auto-contouring system.  
 
DSC and HD values were compared between the groups (manual, 
corrected-auto, and auto) using paired t-test. Contouring time was compared 
using Wilcoxon signed-rank test. P-values were corrected with Bonferroni’s 
correction for group-wise comparisons. P-values <0.05 were considered 
statistically significant. Statistical calculations were performed using SPSS 
software (version 25; IBM Corp, Armonk, NY) and GraphPad Prism Version 8 







1. COMPARISON with ABAS  
 
 
Fig 3. Examples of a) CTV, b) OAR, and c) heart segmentation results of 
DLBAS based on FCDN and ABAS by MIM and Mirada compared against 
ground-truth manual contours.  
 
Figure 3A shows an example of CTV auto-segmentation from ABAS and 
DLBAS. Among 14 CTV structures, DLBAS produced the highest average 
DSCs in 11 of them. The statistical test reflects that these differences were 
significant for left and right AXL3 and IMN (Table 2). However, the HD 
comparisons of CTVs reveal that DLBAS produced smaller surface 
discrepancies compared to ABAS methods in every CTVs except for the SCL 
nodes as shown in Figure 4A. The difference was significant across most 
structures, except for the right AXL1 and SCL nodes. 
 
As for the OARs, the performance of ABAS and DLBAS was comparable: an 
example is shown in Figure 4B. The highest average DSC and lowest HD for 
the lungs and spinal cord was produced by Mirada’s ABAS (0.98 and 2.30mm), 
with the difference in the lungs being statistically significant (Table 3). The 




in the left lung and spinal cord. DLBAS did perform the best for thyroid and 
esophagus but not to a significant extent, as outlined in Table 3.  
 
Figure 3C shows an example of heart auto-segmentation from ABAS and 
DLBAS. In the heart structures, DLBAS produced the highest average DSC in 
five out of seven heart structures (Table 4), with significantly higher results in 
the heart and right ventricle compared to both ABAS solutions. The HD 
comparison between ABAS and DLBAS describes that the average surface 
distance was significantly lower for DLBAS. This is further backed up by the 
smallest range of inter-subject variations in Figure 4C. The segmentation of the 
arteries (RCA and LAD) was below acceptable standards, with all solutions 
having less than a 50% match with the expert manual segmentation. Mirada’s 





Table 2. Comparison of average DSC, HD and their significance for CTV segmentation of the patients in the test set (Mean + 
SD).  
  Right CTVs Left CTVs 




Breast AXL 1 AXL 2 AXL 3 IMN SCL (E) SCL (R) 
















































































































Sig. MIM vs 
Mirada 
<0.01* 0.05 0.15 0.01* <0.01* 0.99 0.12 <0.01* 0.76 0.01* 0.18 0.99 0.70 0.16 
 FCDN vs 
MIM 
<0.01* 0.95 <0.01* <0.01* <0.01* 0.05 0.30 <0.01* 0.04 <0.01* <0.01* <0.01* 0.24 0.69 
 FCDN vs 
Mirada 
0.60 0.18 0.02 <0.01* <0.01* 0.01* 0.68 0.32 0.21 0.14 <0.01* <0.01* 0.34 0.59 
 
HD 

















































































6.5 ± 5.2 8.6 ± 5.7 
Sig. MIM vs 
Mirada 
<0.01* 0.50 0.89 0.06 <0.01* 0.27 0.19 <0.01* 0.61 0.48 0.06 0.10 0.44 0.81 
 FCDN vs 
MIM 
<0.01* 0.44 <0.01* <0.01* <0.01* 0.03 0.07 <0.01* <0.01* <0.01* <0.01* <0.01* 0.07 0.68 











Table 3. Comparison of average DSC, HD and their significance for OAR segmentation of the patients in the test set (Mean + 
SD).  
  Lung R Lung L Thyroid Spinal Cord Esophagus 
 Volume (ml) 1609.1 ± 399.6 1254.4 ± 385.2 25.7 ± 10.2 36.21± 67.0 52.3 ± 9.1 
DSC MIM 0.97 ± 0.01 0.97 ± 0.01 0.76 ± 0.07 0.79 ± 0.07 0.69 ± 0.10 
 Mirada 0.98 ± 0.01 0.97 ± 0.01 0.79 ± 0.06 0.84 ± 0.04 0.72 ± 0.08 
 FCDN 0.96 ± 0.01 0.95 ± 0.02 0.81 ± 0.06 0.81 ± 0.04 0.75 ± 0.05 
Sig. MIM vs Mirada 0.12 0.25 0.15 0.01* 0.05 
 FCDN vs MIM <0.01* <0.01* 0.04 0.42 0.01* 
 FCDN vs Mirada <0.01* <0.01* 0.29 0.10 0.28 
HD MIM 3.6 ± 2.8 2.8 ± 0.6 5.2 ± 2.3 3.5 ± 1.9 9.1 ± 4.8 
 Mirada 2.3 ± 1.2 2.3 ± 0.9 3.9 ± 1.1 3.8 ±3.3 7.0 ± 2.6 
 FCDN 3.9 ± 1.9 6.5 ± 4.3 3.2 ± 1.6 6.4 ± 4.3 5.1 ± 1.9 
Sig. MIM vs Mirada 0.17 0.06 0.02 0.58 0.09 
 FCDN vs MIM 0.67 <0.01* <0.01* 0.06 <0.01* 






Table 4. Comparison of average DSC, HD, and their significance for heart segmentation of the patients in the test set (Mean 
+ SD).  
 
  Heart Atrium R Atrium L Ventricle R Ventricle L RCA LAD 
 Volume 726.0 ± 132.2 88.2 ± 18.4 73.4 ± 22.3 150.6 ± 28.9 199.4 ± 40.6 3.6 ± 1.7 6.5 ± 2.9 
DSC MIM 0.91 ± 0.03 0.79 ± 0.05 0.76 ± 0.08 0.78 ± 0.07 0.84 ± 0.05 0.10 ± 0.10 0.24 ± 0.15 
 Mirada 0.94 ± 0.01 0.83 ± 0.03 0.82 ± 0.05 0.81 ± 0.038 0.88 ± 0.03 0.02 ± 0.06 0.04 ± 0.04 
 FCDN 0.95 ± 0.01 0.85 ± 0.04 0.78 ± 0.04 0.86 ± 0.04 0.87 ± 0.03 0.32 ± 0.14 0.38 ± 0.15 
Sig. MIM vs Mirada 0.01* <0.01* 0.04 0.11 0.03 <0.01* <0.01* 
 FCDN vs MIM <0.01* <0.01* 0.49 <0.01* 0.06 <0.01* 0.02 
 FCDN vs Mirada 0.01* 0.09 0.03 <0.01* 0.10 <0.01* <0.01* 
HD MIM 8.94 ± 4.36 9.79 ± 3.54 9.40 ± 4.26 10.68 ± 3.33 9.14 ± 3.21 20.06 ±7.48 16.98 ± 7.93 
 Mirada 6.09 ± 2.12 7.82 ± 2.22 8.57 ± 4.82 8.45 ±2.06 6.95 ±1.60 NA 52.00 ±23.83 
 FCDN 2.39 ± 0.47 4.03 ±1.20 4.77 ± 2.18 6.15 ±2.39 4.52 ±1.65 8.40 ±7.95 10.17 ± 6.78 
Sig. MIM vs Mirada 0.02 0.04 0.38 0.06 0.02 NA <0.01* 
 FCDN vs MIM <0.01* <0.01* <0.01* <0.01* <0.01* <0.01* <0.01* 





Fig 4. Box-plots of Dice Similarity Coefficients (DSC) and 95% Hausdorff 




Mirada, MIM, and DLBAS based on FCDN using the manual contours as 
reference. 
 
Lastly, Figure 5 shows the results of sensitivity analysis DLBAS and ABAS, 
where the bars indicate the ΔDSC, defined as DSCs of non-contrast test data 
subtracted from DSCs of contrast test data. DLBAS showed much smaller 
ΔDSC compared to ABAS, especially for the CTVs. Similarly, DLBAS 
produced the lowest difference between HD values of contrast and non-contrast 




Fig 5. Difference in dice similarlity coefficients (ΔDSC) between contrast and 






Fig 6. Difference in 95% Hausdorff distance (ΔHD) between contrast and 
non-contrast test sets obtained from fully convolutional DenseNet (FCDN) and 





2. INVESTIGATION OF CLINICAL USEFULNESS  
 
Fig 7. Example of deep learning-based auto-segmentation (green) and manual 
contours (red).  
 
Examples of DLBAS and manual contours are shown in Figure 7. Table 5 
compares the auto-segmented contours and manual contours for OARs and 
CTVs using mean DSC and 95% HD. Regarding OARs, mean DSCs were 
above 0.80 and mean 95% HDs were below 5 mm, which are acceptable results. 
For CTV, the correlation between the auto-segmented and manual contours was 
excellent for breast, with a mean DSC higher than 0.90. As for other CTVs, 
including CTVn_L1, L2, L3, CTVn_IMN, CTVn_L4, and CTVn_SCL RTOG, 
the mean DSCs were mostly higher than 0.70. The mean 95% HD ranged from 
5.50 to 10.93 mm for CTVs. The mean DSCs and 95% HDs did not show a 
large difference between the contrast-enhanced CT test datasets and 
non-contrast CT test datasets.  
 
 Figures 8A and 8B show dose-volume histograms with average 




regional node irradiation, respectively. The increase at the end for the ipsilateral 
breast contour line in the dose-volume histograms is due to the initial RT plan 
that included a simultaneous integrated boost for the tumor bed. As shown in 
Figure 8A, most manual and auto-segmented contours were similar, except for a 
minor difference for the spinal cord. The difference in the delineated spinal cord 
volume (average absolute difference of 7.24 ± 9.07 cc) may have affected the 
results. Figure 8B shows that there was a considerable difference in the 
coverage for regional nodal contours such as axillary lymph node levels 1, 2, 3, 







Fig 8. Comparison of dose-volume histograms with average dosimetric values 
of manual contours (solid line) and auto-segmentation contours (dotted line) for 
patients who received whole breast RT only (A) or that with regional node 





 In addition, various dosimetric parameters for OARs—such as heart, 
lung, esophagus, and spinal cord—were analyzed, as shown in Table 6. The 
mean absolute differences for all parameters were minimal, showing the 




Table 5. Comparison of deep learning auto-segmentation and manual contours of organs-at-risk and target volumes 
 
  Total (n=19)          Contrast (n=10)         Non-contrast (n=9)       


















Organs-at-risk                  
Heart 0.95 0.02  4.56 2.33  0.96 0.01  3.83 2.80  0.94 0.02  5.36 1.27 
Rt Lung 0.98 0.01  3.61 2.15  0.98 0.00  4.64 2.46  0.97 0.01  2.46 0.69 
Lt Lung 0.97 0.01  2.82 0.71  0.97 0.01  3.04 0.76  0.97 0.02  2.59 0.55 
Thyroid 0.89 0.05  1.88 0.90  0.90 0.04  1.55 0.65  0.88 0.05  2.25 0.99 
Esophagus 0.84 0.06  2.87 1.49  0.85 0.05  2.47 0.91  0.83 0.07  3.31 1.85 
Spinal cord 0.82 0.10  2.98 3.10  0.87 0.07  1.58 0.74  0.76 0.10  4.54 3.89 
Target                  
CTVp_breast 0.94 0.04  5.50 3.17  0.94 0.04  5.13 2.74  0.94 0.04  5.91 3.55 
CTVn_L1 0.74 0.08  10.93 6.27  0.71 0.09  13.51 7.10  0.78 0.05  8.07 3.40 
CTVn_L2 0.80 0.07  6.36 2.52  0.79 0.07  6.71 2.40  0.81 0.06  5.98 2.60 
CTVn_L3 0.64 0.13  7.99 3.81  0.66 0.10  6.97 2.87  0.62 0.16  9.11 4.37 
CTVn_IMN 0.72 0.09  5.75 3.36  0.67 0.09  7.53 3.71  0.77 0.07  3.77 1.00 
CTVn_L4 0.74 0.12  6.04 6.12  0.67 0.12  8.37 7.61  0.80 0.09  3.45 1.41 









Table 6. Dosimetric outcomes for maual and auto-segmented contours.  
 
 Manual   Autocontour   Absolute difference 
 Mean STD  Mean STD  Mean STD 
Heart         
   Mean (Gy) 3.27 1.10  3.26 1.10  0.08 0.07 
   D0.03cc (Gy) 22.72 10.24  21.75 9.68  1.51 1.76 
   V5Gy (cc) 16.08 10.23  16.13 10.39  0.73 0.75 
Lung         
   Ipsilateral lung mean (Gy) 6.87 0.97  6.82 0.97  0.11 0.18 
   Ipsilateral lung V20Gy (%) 10.08 2.59  9.82 2.68  0.36 0.35 
   Ipsilateral lung V5Gy (%) 35.25 5.15  35.46 5.32  0.67 0.98 
   Contralateral lung mean (Gy) 1.83 0.66  1.84 0.67  0.02 0.03 
Esophagus         
   D0.03cc (Gy) 7.82 5.16  7.56 4.73  0.85 1.61 
Spinal cord         






To confirm whether DLBAS can practically serve as a useful tool in clinical 
practice, qualitative scores were also analyzed. Qualitative scoring was 
performed by both an expert (n = 11) and a non-expert panel (n = 15) for 
difference and assistance scores, as shown in Figure 4. For OARs, the median 
difference score was 9 (range, 8–10) and the median assistance score was 9 
(range, 8–10), in the case of the expert panel. The scores were similar for OARs 
in the case of the non-expert panel, with a median difference score of 8 (range, 
6–10) and a median assistance score of 9 (range, 8–10). For CTVs of breasts 
and regional lymph nodes, the median difference score was 8 (range, 7–9) and 
the median assistance score was 9 (range, 7–10), in the case of the expert panel. 
Regarding the non-expert panel, the median difference score was 8 (range, 





3. EXTERNAL VALIDATION  
 
After conducting the process of the study, we collected 110 manual contours, 
110 corrected-auto-contours, and 10 auto-contours of each type of OAR. When 
these contours were compared to the consensus ground truth contours, 100 DSC 
and 100 HD values (pairs of the ground truth contour and each contour) were 
created for each types of OARs for manual and corrected-auto-contours, 
respectively, and 10 DSC and 10 HD values for auto-contours.   
 
Table 7 and Figure 9 shows the mean DSC and HD values of manual, 
corrected-auto-, and auto-contours by each OAR. The DSC of breast contours 
were prominently higher in the corrected-auto-contours or auto-contours than in 
the manual contours; the absolute differences of DSCs between the manual and 
corrected-auto contours were 0.09 in the right breast and 0.07 in the left breast, 
while those of the other OARs were less than 0.03. The HD values of the breast, 
heart, and liver contours showed prominent differences; the HDs of breast and 
heart contours were prominently lower in the corrected-auto-contours or 
auto-contours compared than in the manual contours. In contrast, the HD of 
liver contours was prominently higher in the auto-contours than in the manual 
or corrected-auto-contours.  
 





In the cases of the breast, spinal cord, and heart contours, 
corrected-auto-contours had better accuracy than manual contours, which is 
consistently seen in DSC and HD values. In contrast, in cases of the thyroid and 
lung contours, the manual contour had better accuracy than the 
corrected-auto-contour, which is consistently seen in DSC and HD values. In 
the cases of liver and esophagus contours, mixed results were shown; DSCs 
were higher in the manual contours, but the HDs were lower in the 
corrected-auto-contours. The results of the sensitivity analyses were in 
consistent with the original analyses (Table 8 and Fig 10). The results of 
statistical analyses for contour comparisons are shown in Table 8 and 9. 
 
 
Fig 10. Dice similarity coefficient (A) and Haudorff distance values (B) 
according to the organ-at-risks, comparing manual contours, 
corrected-auto-contours, and auto-contours. For sensitivity analyses, contouring 
metrics were obtained by comparing each contour with the second-best contour. 
Data are shown in mean ± standard error. 
 
To evaluate the performance of auto-contour itself, the DSC and HD values of 
all OARs were compared between manual and auto-contours. In manual 
contours, the mean DSCs of all OARs ranged from 0.86 to 0.90 (median, 0.88) 




(median, 6.44 mm). Based on the mean DSCs of all OARs, the auto-contour 
ranked 2nd place with a value of 0.896, following the expert whose value was 
0.903. Based on the mean HDs of all OARs, auto-contour ranked 1st place with 
a value of 5.142 mm, followed by the expert whose value was 5.327 mm (Table 
10).  
 
The inter-physician variations observed in the experts’ manual contours were 
reduced in the corrected-auto-contours. The range of mean DSC of all OARs 
was 0.86–0.90 according to the individuals in manual contours but reduced to 
0.89–0.90 in corrected-auto-contours. The range of mean HD of all OARs was 
5.14–9.19 mm according to the individuals in manual contours but reduced to 
4.3–5.7 mm in corrected-auto-contours. Figure 11 shows the mean DSCs 
according to the OARs. The figure shows that DSCs were more homogeneous 
in the corrected-auto-contours than in the manual contours, meaning that 
inter-physician variability was reduced. Contours of a medical student were also 
shown in the figure, showing the improved accuracy in the 
corrected-auto-contours like other experts. A sensitivity analysis was shown in 
figure 12 and showed the consistent results to the original analyses. Examples 
of manual and corrected-auto contours of breast and heart are shown in Fig 13. 
Notably, the inter-physician variability of manual breast contours was mostly 
seen in the lateral and anterior borders of the breast, while this variability was 






Fig 11. Radar graphs showing mean DSC value of each participant according to 
the organs: (A) manual contours, (B) corrected-auto-contours. DSC values of 
corrected-auto-contours were more homogeneous than those of manual contours 
meaning that inter-physician variability was reduced. 
 
 
Fig 12. Radar graphs showing mean DSC value of each participant according to 
the organs: (A) manual contours, (B) corrected-auto-contours. DSC values of 
corrected-auto-contours were more homogeneous than those of manual contours 
meaning that inter-physician variability was reduced. For sensitivity analyses, 







Fig 13. Examples of manual and corrected-auto-contours of all experts: (A) 
breast contours showing that inter-physician variability is mostly seen in lateral 
and anterior borders of breasts and is reduced with an aid of auto-contouring 
system, as well as (B) heart contours. 
 
Mean contouring time for 9 OARs of each patient was 37 min (standard 
deviation [SD], 20 min) for manual contours and 6 min (SD, 5 min) for 
corrected-auto-contours, showing 84%-time reduction with an aid of 
auto-contouring system (Fig. 14A and Table 11). When mean time was 
measured according to each OAR, breast and liver contouring was the longest 
step among the manual contours. The time was prominently reduced in the 
corrected-auto-contours (right breast: 5.9 min [SD, 3.8 min] to 0.5 min [SD, 1.1 
min]; left breast: 6.3 min [SD, 4.1 min] to 0.6 min [0.7 min]; liver: 9.0 min [SD, 







Fig 14. Contouring time comparing manual contouring and correcting 
auto-contours: (A) total contouring time of all 9 organ-at-risks of each expert, 
(B) contouring time of each organ-at-risks. Data are shown in mean ± standard 
error. 
 
The mean score of the question, “how was the accuracy of auto-contours?”, was 
7.5±0.9, that of the question, “how much auto-contours helped to shorten the 
contouring time?”, was 8.8±1.1, and that of the question, “Do you want to use 
auto-contours in future practice”, was 9.2±0.7, where the answers were 




Table 7. Summary of Dice Similarity Coefficient and Hausdorff distance  
 Dice Similarity Coefficient (mean±SD)   Hausdorff distance (mean±SD) 
 Manual contour Corrected-auto-contour Auto-contour   Manual contour Corrected-auto-contour Auto-contour 
Thyroid 0.8±0.06 0.8±0.06 0.79±0.07  3.82±2.03 4.12±2.56 4.28±2.62 
Lung_right 0.98±0.02 0.97±0.01 0.97±0.01  2.37±1.49 2.46±0.92 2.42±0.93 
Lung_left 0.97±0.02 0.96±0.02 0.96±0.02  3.61±3.46 2.93±1.77 2.99±2.11 
Breast_right 0.81±0.05 0.9±0.02 0.91±0.01  12.44±7.96 8.06±3.48 7.54±2.05 
Breast_left 0.83±0.04 0.9±0.02 0.9±0.03  10.85±5.83 8.14±3.29 8.15±3.32 
Spinal cord 0.82±0.07 0.85±0.03 0.85±0.03  3.95±5.37 2.2±0.35 2.21±0.36 
Esophagus 0.84±0.04 0.83±0.03 0.82±0.03  3.95±3.64 3.16±0.59 3.46±0.68 
Heart 0.92±0.03 0.94±0.01 0.95±0.01  8.26±5.47 5.42±2.85 4.73±1.05 
Liver 0.94±0.02 0.94±0.02 0.93±0.02  6.92±6.36 5.95±3.22 9.74±9.98 




Table 8. Summary of Dice Similarity Coefficient and Hausdorff distance  
  Contour   P-value* 
  (1) Manual (2) Corrected-auto (3) Auto   (1) vs (2) (1) vs (3) (2) vs (3) 
DSC 
(mean±SD) 
Thyroid 0.8±0.06 0.8±0.06 0.79±0.07  .953 .042 .014 
Lung_right 0.98±0.02 0.97±0.01 0.97±0.01  <.001 <.001 .262 
Lung_left 0.97±0.02 0.96±0.02 0.96±0.02  <.001 <.001 .801 
Breast_right 0.81±0.05 0.9±0.02 0.91±0.01  <.001 <.001 .596 
Breast_left 0.83±0.04 0.9±0.02 0.9±0.03  <.001 <.001 .280 
Spinal cord 0.82±0.07 0.85±0.03 0.85±0.03  .001 .001 .136 
Esophagus 0.84±0.04 0.83±0.03 0.82±0.03  .001 <.001 <.001 
Heart 0.92±0.03 0.94±0.01 0.95±0.01  <.001 <.001 .029 
Liver 0.94±0.02 0.94±0.02 0.93±0.02   <.001 <.001 <.001 
HD 
(mean±SD) 
Thyroid 3.82±2.03 4.12±2.56 4.28±2.62  0.33 0.056 0.021 
Lung_right 2.37±1.49 2.46±0.92 2.42±0.93  >.999 >.999 0.472 
Lung_left 3.61±3.46 2.93±1.77 2.99±2.11  0.077 0.115 0.538 
Breast_right 12.44±7.96 8.06±3.48 7.54±2.05  <.001 <.001 0.284 
Breast_left 10.85±5.83 8.14±3.29 8.15±3.32  <.001 <.001 >.999 
Spinal cord 3.95±5.37 2.2±0.35 2.21±0.36  0.005 0.005 0.475 




Heart 8.26±5.47 5.42±2.85 4.73±1.05  <.001 <.001 0.034 
Liver 6.92±6.36 5.95±3.22 9.74±9.98   0.335 0.085 0.002 
Abbreviations: DSC, Dice similarity coefficient; HD, Hausdorff distance; SD, standard deviation 




Table 9. Summary of Dice Similarity Coefficient and Hausdorff distance for sensitivity analyses.  
    Contour   P-value* 
    Manual Corrected-auto Auto   MS vs AS+R MS vs AS AS+R vs AS 
DSC 
(mean±SD) 
Thyroid 0.78±0.07 0.77±0.06 0.77±0.06  0.942 1.031 >.999 
Lung_right 0.96±0.02 0.97±0.01 0.96±0.01  0.099 0.214 0.336 
Lung_left 0.96±0.02 0.96±0.02 0.96±0.02  >.999 0.441 0.04 
Breast_right 0.83±0.04 0.87±0.03 0.87±0.03  <.001 <.001 0.355 
Breast_left 0.85±0.04 0.88±0.03 0.88±0.03  <.001 <.001 0.971 
Spinal cord 0.85±0.06 0.89±0.03 0.89±0.03  <.001 <.001 >.999 
Esophagus 0.8±0.04 0.75±0.03 0.74±0.03  <.001 <.001 <.001 
Heart 0.89±0.03 0.9±0.03 0.9±0.02  0.007 0.001 0.066 
Liver 0.95±0.02 0.94±0.02 0.93±0.02   <.001 <.001 <.001 
HD 
(mean±SD) 
Thyroid 4.16±1.94 3.99±1.28 3.98±1.07  0.956 0.962 >.999 
Lung_right 4.04±2.01 4.12±1.62 4.29±1.63  >.999 0.421 0.003 
Lung_left 3.45±2.01 3.54±1.98 3.84±2.49  >.999 0.045 0.006 
Breast_right 14.28±6.64 11.7±4.88 11.87±5.11  0.001 0.005 >.999 
Breast_left 11.51±3.98 9.27±3.54 9.5±3.87  <.001 0.002 0.524 
Spinal cord 2.15±0.5 1.71±0.34 1.73±0.32  <.001 <.001 0.134 




Heart 12.9±6.36 12.99±5.59 12.21±5.11  >.999 0.99 0.015 
Liver 6.11±3.24 6.83±3.46 10.37±8.53   0.258 <.001 0.001 
Abbreviations: DSC, Dice similarity coefficient; HD, Hausdorff distance; SD, standard deviation 




Table 10. The DSC and HD values of all OARs of experts’ manual contours and an auto-contour, listed from the best to the 
lowest performance.  
Rank DSC HD 
  Average (Standard deviation) 
1 0.903 (0.065) 5.142 (2.692)* 
2 0.896 (0.06)* 5.327 (3.623) 
3 0.887 (0.062) 5.477 (3.055) 
4 0.886 (0.061) 5.615 (3.543) 
5 0.882 (0.066) 5.78 (3.72) 
6 0.881 (0.06) 6.431 (4.818) 
7 0.881 (0.076) 6.447 (5.938) 
8 0.88 (0.09) 6.461 (4.021) 
9 0.877 (0.067) 6.501 (4.072) 
10 0.874 (0.08) 6.724 (6.298) 
11 0.87 (0.087) 7.636 (7.014) 




Table 11. Total contouring time for 9 organ-at-risks of each patient 
  Manual (min) Correced-auto (min) Difference* (min) 
Expert 1 36.4 19.1 17.3  
Expert 2 26.9 4.2 22.6  
Expert 3 16.0 2.6 13.4  
Expert 4 23.2 4.8 18.4  
Expert 5 43.9 3.2 40.7  
Expert 6 18.7 9.8 8.9  
Expert 7 8.1 2.2 5.9  
Expert 8 59.4 5.5 53.9  
Expert 9 70.8 8.7 62.1  
Expert 10 61.2 6.2 55.1  
Expert 11 47.1 4.4 42.7  
Mean 37.4 6.4 31.0 
SD 19.7 4.6 19.4 
Abbreviations: SD, standard deviation 
























Expert 1 4.3 1.3 1.5 5.1 6.1 1.2 4.4 3.7 8.0 
Expert 2 1.7 1.4 0.6 5.8 6.2 1.2 1.6 1.7 5.9 
Expert 3 1.7 0.4 0.8 1.8 1.7 0.9 2.3 1.6 3.6 
Expert 4 2.0 0.5 0.6 1.8 2.4 1.3 2.3 1.6 7.2 
Expert 5 2.4 4.9 3.9 6.1 6.7 3.2 4.1 4.3 7.5 
Expert 6 1.8 0.9 0.9 2.6 2.3 0.8 2.1 1.7 5.7 
Expert 7 1.1 0.6 0.4 0.8 0.8 0.7 0.5 1.1 1.6 
Expert 8 4.0 3.3 2.2 11.2 10.7 4.0 6.7 6.2 11.1 
Expert 9 5.4 1.9 1.3 12.8 14.8 4.3 7.9 6.2 16.1 
Expert 10 7.0 1.7 1.0 8.7 8.9 2.8 7.3 6.2 17.6 
Expert 11 4.1 1.2 0.6 8.7 8.7 2.0 3.4 3.3 15.1 
Mean 3.2 1.6 1.2 5.9 6.3 2.0 3.9 3.4 9.0 
SD 1.8 1.3 1.0 3.8 4.1 1.3 2.4 2.0 5.0 
























Expert 1 1.4 0.2 1.2 3.9 2.4 0.6 2.5 2.4 3.5 
Expert 2 0.1 0.1 0.1 0.4 0.5 0.0 0.2 0.4 1.2 
Expert 3 0.1 0.1 0.1 0.0 0.2 0.0 0.8 0.0 0.6 
Expert 4 0.7 0.1 0.1 0.1 0.2 0.2 0.6 0.4 1.0 
Expert 5 0.1 0.5 0.2 0.1 0.1 0.3 0.1 0.0 0.4 
Expert 6 1.1 0.1 0.0 0.1 0.9 0.1 1.5 1.2 4.2 
Expert 7 0.1 0.2 0.1 0.0 0.0 0.1 0.0 0.3 0.7 
Expert 8 0.7 0.1 0.2 0.6 1.1 0.2 1.8 0.2 0.6 
Expert 9 1.1 0.7 0.3 0.2 0.6 0.3 3.6 1.0 1.0 
Expert 10 0.8 0.1 0.1 0.0 0.1 0.0 3.7 0.1 1.4 
Expert 11 0.5 0.2 0.2 0.0 0.1 0.0 1.1 0.4 1.9 
Mean 0.6 0.2 0.2 0.5 0.6 0.2 1.5 0.6 1.5 
SD 0.4 0.2 0.3 1.1 0.7 0.2 1.3 0.7 1.2 








A. COMPARISON with ABAS 
 
To the best of our knowledge, this is the first study that compares the 
performance of ABAS and DLBAS methods for breast cancer RT planning that 
includes node regions and heart structures. In this study, we demonstrated the 
efficacy of our DLBAS by measuring the performance across a range of 
structures (CTVs, OARs, and heart) in a head-to-head comparison study with 
commercial ABAS solutions. Our results indicate that, while ABAS offered an 
acceptable performance level, DLBAS showed much more robust and reliable 
automatic segmentation outcomes that were in greater spatial similarities with 
the ground-truth. These findings are parallel with several studies comparing 
ABAS and DLBAS methods in other malignancies. Lustberg et al. were the first 
to compare the delineation by a commercial DLBAS program with those 
obtained by an ABAS program in five OARs for lung cancer.34 Other studies 
have compared the ability of a commercial ABAS program and a convolutional 
neural network (CNNs)-based DLBAS to delineate OARs found in liver 
cancer35 and lung cancer; these studies provided evidence that DLBAS is more 
accurate and computationally faster than ABAS.   
 
DLBAS had a competitive edge on their ABAS counterparts in general, 
especially in some CTVs (e.g. AXL3 and IMN) and heart structures in terms of 
both DSC and HD. Our finding with respect to high performance of DLBAS in 
heart structures (overall chamber accuracy of 0.86) is better, or at least similar, 
than previous studies. Jung et al. reported average DSCs of 0.66 in the atria and 
0.75 in the ventricles with ABAS approach.36 Dormer et al. reported good 




heart substructures trained on 11 3D CT data.37 In this study, the performance of 
ABAS was below a satisfactory level in coronary arteries (RCA, LAD), which 
is similar with two previous studies37,38 that both reported a mean DSC less than 
0.3. On the other hand, DLBAS and ABAS demonstrated a comparable 
performance in the OARs. The OAR structures tend to have distinct structural 
boundaries, which would have worked in favour of ABAS’ intensity-based 
registration.  
 
Our results are indicative of three important findings for DLBAS. Firstly, we 
highlighted the ability of DLBAS in learning the characteristics of complex and 
low-contrast anatomy, implying its potential for CTV delineation where the 
quality of delineation is highly dependent on expert knowledge. Conversly, it 
indicates the limitation of ABAS in this perspective as it is based on 
landmark-based detection. Secondly, the fact that DLBAS has much smaller 
contouring differences with the ground-truth (on the order of millimeters as 
indicated by HD) highlights the clinical impact of its implementation. Although 
widely used in the literature, DSC is often highly affected by the volume size of 
the two contours under comparison which is the reason why distance metrics 
like HD were introduced for evaluation. If auto-segmented contours were to be 
modified in a clinical setting, HD values are likely to be an important factor that 
determines the time taken for modifications as its values are directly linked to 
the accuracy of the contour outlines, more so than the DSC. Based on the 
statistical analysis of our DSC and HD results, we believe that DLBAS could be 
a solution that can reduce the time required for generating contours of the CTVs 
and heart substructures than ABAS. Thirdly, our finding with respect to 
robustness of DLBAS on non-contrast CT test samples is noteworthy. DLBAS 
showed much smaller DSC discrepancies between contrast and non-contrast 




model is less dependent on the type of input than ABAS, hence could be more 
robust, making it is beneficial in clinical settings where patient data are not 
always collected with consistent protocols such as CT contrast. 
 
Based on the results, DLBAS has great potential to be the solution for many 
issues encountered in RT planning. First and foremost, it can address the 
consistency issue of manual contouring in practice and large-scale clinical 
studies. Weber et al. discussed that large inter-physician and inter-institutional 
variations are one of the biggest challenges in today’s radiation oncology 
trials.39 Up to 13.4% of assessed RT plans in clinical trials were deemed 
unacceptable due to major deviations in target volume delineations.40 This is 
problematic due to the associated safety issues and toxicity from incorrect 
delineations. A recent survey that investigated inter-institutional variations in 
breast IMRT in South Korea has revealed that there are large heterogeneities in 
the target volume and RT plans between practices. If these contours can be 
generated in a consistent manner using DLBAS, the burden and possible 
complications in these trials may be avoided. However, implementing DLBAS 
comes with initial time and cost investments involving purchasing or building a 
reliable DLBAS model specifically designed for each institution, which 
involves patient data collection and generation of the ground-truth labels by the 
experts. However, once this foundation work is completed, the time spent for 
repetitive work (i.e. contouring) will be greatly reduced, which would 
subsequently allow us to attend to other clinical activities in the department.  
 
B. INVESTIGATION OF CLINICAL USEFULNESS  
 
Our findings suggest that the proposed algorithm performed well, exhibiting 




clinical experts from both qualitative and quantitative aspects. The dosimetric 
implications of the auto-contours were also evaluated, and we did not observe 
any significant difference in dose-volume histograms between the 
auto-segmented contours and manual contours.  
  
Although AI solutions are best suited to situations in radiology where ground 
truths are clear, the concept of a ground truth in RT fields is disputable because 
RT is both a science and an art entailing clinical input and creativity 41. More 
specifically, inter-physician variations are present even in contours delineated 
by board-certified radiation oncologists from the same institution (e.g., 
variations in the nodal target volumes in our study; Additional file 1). We 
acknowledge that the generation of the same contours by an AI algorithm under 
multiple scenarios does not mean that the generated contours are optimal. 
Considering this, we collected data based on the assumption that the 
international guidelines are an alternative ground truth.28,42 Although the 
proposed algorithm performed well, a risk exists that its reliability may decrease 
in some situations.43  
 
In 2006, Eldesoky et al. first reported the clinical utility of ABAS in 
loco-regional RT for breast cancer using the data of 60 patients, where 
delineation was performed according to the ESTRO consensus guideline.44 
ABAS showed good agreement in some volumes (e.g., lung, heart, and breast), 
whereas it showed only modest agreement in other structures or in external 
datasets. However, research interest shifted to DLBAS because ABAS had 
several limitations; thus, we recently published a study comparing the 
performance of DLBAS with that of two commercially available ABAS systems 
for breast cancer RT.45 In this study, the deep learning-based approach showed 




this performance gap increased substantially for soft-tissue-based regions and 
smaller volumes.  
 
DLBAS has been widely investigated in head & neck, lung, and prostate 
cancers, and has demonstrated clinically relevant impact regarding saving time 
and mitigating inter-observer variability.25,26,46 Although several studies have 
reported the feasibility of the deep learning-based approach for the breast, 
training and testing has only been performed for ipsilateral breast CTVs.47,48 In 
this study, a satisfactory DSC of 0.94 for CTVp_breast was shown, which is 
similar with that obtained for other series using the deep learning-based 
approach. One study using a dataset of 800 patients with a deep learning 
algorithm (DD-ResNet) showed a mean DSC of 0.91 for the CTVs of both 
breasts.47 Furthermore, similar with the study by Eldesoky et al., in which they 
tested ABAS, we performed training not only for whole breast CTVs but also 
for various OARs and other CTVs, including regional lymph nodes in breast 
cancer patients. The current DLBAS model showed higher performance in 
segmenting various OARs—including heart, lung, thyroid, esophagus, and 
spinal cord—that were large and well-defined. As for regional lymph nodes, 
because of the smaller volumes and less well-defined borders, the current model 
exhibited modest performance. Regarding qualitative scoring, the expert and 
non-expert panels gave high difference and assistance scores for both the OARs 
and CTVs. 
 
To date, even with fully validated auto-segmentations, modification or 
correction by clinical experts is commonly accepted. However, whether 
modification or correction is essential when auto-contours are utilized for 
dosimetric analysis has not been well studied. In this study, dosimetric analysis 




and auto-segmented contours for OARs. However, as for CTVs, particularly for 
the axillary lymph node regions and IMN, there were some discrepancies 
between manual and auto-segmented contours. For OARs, it can be suggested 
that auto-segmented contours can be used for dose-response related studies or 
predicting normal tissue complication probability in clinic. However, for CTVs, 
auto-contours in target volumes need significant modification by experts to 
conform to the corresponding anatomy and to individualize according to tumor 
and patient information. In the area of research, auto-segmented CTVs can be 
used as a reference point when comparing target volume delineation of various 
participants.  
 
In breast cancer trials, variations in target delineation and RT planning have 
become a prominent issue, particularly in multidisciplinary trials that lack RT 
quality assurance programs.49 In a recent audit study across a large network, it 
was found that nodes were not contoured or the contour quality was inadequate 
for 18% of patients.50 In a Korean study that investigated inter-institutional 
variations in breast IMRT (KROG 19-01), there were large heterogeneities in 
the target volume as well as OARs, producing large variations in mean heart 
dose and lung V20Gy (up to five times in the same dummy run case). We 
believe that our auto-segmented contours of CTVs and OARs can play an 
important role in the breast RT quality assurance process, as illustrated in Chen 
et al.’s study.48 Nationwide quality assurance is underway in Korea with our 
proposed algorithm.  
 
Accurate delineation of all OARs and CTVs is a laborious task; here, 
auto-segmentation can serve as a useful tool in reducing the workload on 
physicians. In a previous study on ABAS for loco-regional RT of breast cancer, 




before correction by 93% and after correction by 32%.44 This study showed a 
similar potential, with average times of 39 min and 10 min for manual 
delineation and DLBAS, respectively. With the assistance of DLBAS, radiation 
oncologists will be able to work more efficiently. Qualitative subjective scoring 
by the expert and non-expert panels exhibited satisfactory results for both 
difference and assistance scores, showing that DLBAS can serve as a helpful 
tool in real-world clinics.  
 
C. EXTERNAL VALIDATION  
 
Using our deep-learning based auto-contouring system, we compared the 
performance between manual contours from multiple experts, corrected-auto 
contours, and auto-contours in OARs for breast cancer radiotherapy. As a result, 
auto-contours were shown to have at least similar performance with manual 
contours of experts, shown by that average DSC and HD of auto-contours 
ranked second and first place, respectively, among the experts’ manual contours. 
The inter-physician variation shown in manual contours was reduced with an 
aid of auto-contouring system. Moreover, the time for contouring was 
substantially reduced with an aid of auto-contouring system, with good user 
satisfaction.  
 
Notably, in cases of breast contours, auto-contours or corrected auto-contours 
showed especially better accuracy than manual contours. The DSC values were 
improved by 0.09 (right breast) and 0.07 (left breast) in the 
corrected-auto-contours compared with the manual contours, while those with 
other OARs were mostly within 0.02. The HD values were also improved by 
4.38 mm (right breast) and 2.71 mm (left breast), while those with other OARs 




auto-contouring system than manual contouring alone. In contrast, in cases of 
liver contours, HD values were prominently high in the auto-contours and 
reduced in the corrected-auto-contours to the similar value of manual contours, 
which means that manual adjustment was necessary. Therefore, the performance 
of manual contouring and auto-contouring are similar in general, but the 
detailed performance seems vary depending on the OARs.  
 
We observed substantial inter-physician variability between the experts’ manual 
contours. Substantial variability in manual contouring the targets and OARs 
between the institutions and observers has been shown in RTOG 
multi-institutional and multiple-observer study.14 Such inter-physician 
variability is obstacle in accurate assessment of the efficacy of radiotherapy and 
the risk of long-term side effect. Incidental radiation exposure to the heart 
during breast RT increases the risk of heart disease, considering the 
dose–response relationship between heart radiation dose and acute coronary 
event.10,51 Moreover, radiation-related hypothyroidism,9 radiation pneumonitis,52 
and secondary contralateral breast cancer53 have been reported in patients with 
breast cancer. In addition, in clinical trials including radiotherapy, there is a 
problem of standardization of treatment with this variability in delineating target 
and OARs.54 In the RTOG 0617 trial, a radiation dose escalation trial in 
non-small cell lung cancer, an analysis using deep-learning segmented hearts 
showed that the actual heart doses were higher than originally reported due to 
the inconsistent and insufficient heart segmentation.55 Our results showed that 
this problem can be solved by applying auto-contouring system. For example, 
the lateral border of breast had the largest variation among the experts’ manual 
contours in this study. Because the most widely used RTOG56 and ESTRO 
guidelines13 define the lateral border of breast as clinically palpable breast or 




auto-contouring system can help to standardize the delineation when the 
definition of the boundary of organ is ambiguous. Of note, a medical student 
who had no experience in breast cancer radiotherapy had bad performance in 
manual contouring but had comparable performance to other experts with an aid 
of auto-contouring system. This shows the potential that the learning can be 
sharper with an aid of auto-contouring system for training radiation oncology.  
 
The manual adjustment of auto-contour had an average time reduction of 84% 
compared to the manual contouring. The time reduction was most remarkable in 
breast and liver contouring, which took the longest manual contouring time. 
When adjusting the auto-contour, the average time taken for each organ was less 
than 1 minute, which means that only minimal or no correction was needed. 
Adjusting liver and esophagus auto-contours took relatively longer time, but it 
was only 1.5 minutes, respectively. In addition, participants responded that 
auto-contouring system helped to shorten the time and would like to use it in the 
future. Considering that symptoms of burnout have been reported in >1 of every 
2 practicing physician and this affliction,57 which can be largely driven by 
work-related stressors,58 efforts are needed to reduce the work loading of 
physicians, and ACS can be used for this. 
 
Our study had several limitations. First, focusing on contours produced by a 
single expert had both positive and negative effects. One positive effect was that 
we were able to test each model’s performance in a more controlled manner 
without introducing additional sources of variability. However, as mentioned 
earlier, we are aware that inter-observer variations exist and that this may affect 
the overall performance, so additional studies involving multiple experts will be 
necessary to test the robustness of our methods. Furthermore, since the findings 




further studies are required with external validation involving multiple experts. 
Finally, we did not optimize the ABAS for each software package. Since Mirada 
does not offer any options for algorithm adjustment per its policy, we simply 
sent the planning CT to the WFB server to generate the ABAS contours. 
Although MIM offers the tools for modifying and correcting the match between 
the template and the new subject during fusion and registration to ensure better 
ABAS outcomes, none of the edits were made in this study to maintain 
consistency with Mirada. Additionally, we carried out a simultaneous ABAS, 
where we segmented all the structures simultaneously. Due to a wide 
discrepancy in patient size, organ shape, and displacement, carrying out this 







Compared to ABAS, DLBAS was more consistent and robust in its performance 
across most structures. In this clinical study, we have confirmed the plausibility 
of these segmentation solutions for clinical implementations. This study also 
showed the potential and feasibility for DLBAS for breast cancer patients 
receiving RT after breast-conserving surgery. Although DLBAS cannot serve as 
a substitute for the experience of radiation oncologists, it has the potential to 
serve as a useful tool in assisting them. In addition, ACS showed at least similar 
performance in OARs compared with experts’ manual contouring, which 
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ABSTRACT (IN KOREAN) 
 
유방암 환자 방사선 치료의 정상 장기 및  
치료 체적의 자동 구획화 
 
<지도교수 금 기 창> 
 
연세대학교 대학원 의학과 
 
장 지 석 
 
목적: 유방암 방사선 치료에서 치료 체적에 대한 정확한 타겟 
그리기는 중요하다. 하지만 방사선 치료 계획 과정에 타겟 
그리기는 의료진의 부담을 주고 있으며, 의료진 간의 편차는 
존재하고 있다. 본 연구에서는 Deep learning-based 
auto-segmentation (DLBAS)의 성능을 atlas-based segmentation 
solutions (ABAS)와 비교하고, 임상 의사의 관점에서 유용성을 
평가하고, 최종적으로 외부 타당도 조사를 통하여 유방암 
방사선 치료에서 자동 구획화의 가능성을 규명하고자 한다.  
 
대상 및 방법: 유방암 방사선 치료 체적과 정상장기들에 대하여 
한 명의 연구진에 의하여 구획화 정보를 생성하였다. 
Convolutional neural network 알고리즘을 이용하여 auto-contours를 
생성하였고, Dice similarity coefficient (DSC) and 95% Hausdorff 
distance (HD)를 이용하여 ABAS와 비교하였다. DLBAS에 의해 
생성된 auto-contours의 질적인 평가를 조사하였고, manual 
contours와 방사선 치료 선량-체적 히스토그램을 비교하여 주요 
선량평가분석을 시행하였다. 마지막으로 2개 기관의 11명의 
전문가에게 manual contour를 그릴 것을 요청하여 데이터를 




선정하였고, 나머지 10명의 contour와 DLBAS에 의해 생성된 
auto-contour의 성능을 비교하여 순위 평가를 시행하였다.  
 
결과: 제안된 DLBAS 모델은 대부분의 체적 (특히, 치료 체적과 
심장 세부구조)에서 ABAS보다 더 일관된 결과와 높은 DSC와 
낮은 HD 결과 값을 보였다. ABAS는 연조직의 정상장기와 
조영제를 쓰지 않은 새로운 데이터 셋에서 DLBAS에 비해, 
제한적인 성능을 보였다. 질적 평가를 위한 설문조사가 
시행되었고, 중위수 8점으로 manual contour와 auto-contour 
사이의 차이가 크지 않다고 대답하였으며, 임상에서 도움이 될 
것으로 답변하였다. 또한 선량평가 분석 결과에서 차이는 
미미하였다. 외부 검증 결과, 9개의 정상장기를 그리는데 평균 
37분이 걸렸고, DLBAS는 6분이 걸렸다. Auto-contour는 전체 
12개 중 1위 manual contour와 비교하였을 때 가장 DSC상 
차이가 적었으며, HSD상 2번째로 차이가 적었다. 정상장기에서 
가장 편차가 높았던 부위는 유방이었다.  
 
결론: 유방 방사선 치료 계획에서 DLBAS의 실현가능성은 이번 
연구에서 다각도로 검증되었다. 의료진의 최종 수정 과정은 
필수적이지만, 앞으로 DLBAS는 방사선 치료를 도울 수 있는 
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